Search clinical trials for: TOLVAPTAN

Total 123 results

Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Unknown

Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease (METROPOLIS)

ADPKD

Italy
Lisbet Brandi

Unknown

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease (PoCKET)

Autosomal Dominant Polycystic Kidney

Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Graft-Versus-Host Disease (GVHD) Acute on Chronic

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Colorectal Cancer | Metastatic Cancer

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, United Kingdom, Italy
Polderman, Kees, H., MD, PhD
University of Pittsburgh

Terminated

Tolvaptan for Patients With Acute Neurological Injuries

Hyponatremia | SIADH

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Cardiology Research UBC

Unknown

Regional Tolvaptan Registry (Tolvaptan)

Hyponatremia | Decompensated Heart Failure

Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Europe Ltd

Completed

An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH (SAMPLE)

Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

Germany, Spain
NYU Langone Health
Otsuka America Pharmaceutical

Terminated

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Hyponatremia

United States
Postgraduate Institute of Medical Education and...

Completed

Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites

Cirrhosis | Refractory/Recurrent Ascites

India
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

Heart Failure With Hyponatremia

Korea, Republic of
Translational Research Center for Medical Innovation...
Nippon Medical School, Musashi Kosugi Hospital

Completed

Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure (MT FUJI)

Heart Failure

Japan
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Heart Diseases | Cardiovascular Diseases | Heart Failure

United States
Duke University

Completed

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure (TACTICS-HF)

Heart Failure | Dyspnea

United States
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TOPO)

Autosomal Dominant Polycystic Kidney Disease

Denmark
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) (DOVA)

Nephropathy

Denmark
Novo Nordisk A/S

Completed

Treatment of Congenital Factor VII Deficiency (F7CONDEF)

Congenital Bleeding Disorder | Congenital FVII Deficiency

Slovakia, Israel, Spain, India, Iran, Islamic Republic of, Pakistan, Turkey, Germany, Serbia, Italy, Greece, Thailand, France, United States, Hong Kong, Venezuela
Shanghai Chest Hospital

Completed

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Right Heart Failure | Tricuspid Regurgitation

China
Mario Negri Institute for Pharmacological Research
A.O. Ospedale Papa Giovanni XXIII

Terminated

Tolvaptan for In-hospital Hyponatremia (INSERT)

Hyponatremia

Italy
Northwestern University
Otsuka America Pharmaceutical

Completed

Effects of Tolvaptan in Healthy Adults

Healthy

United States
Cardiovascular Clinical Science Foundation

Completed

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management (Secret of CHF)

Heart Failure

United States
University of North Carolina, Chapel Hill
Medical University of South Carolina; Otsuka America Pharmaceutical; Barnes-Jewish...

Terminated

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

Brain Injury | Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Germany, United Kingdom, Spain, Sweden, Hungary, Czech Republic, Denmark
Oakland University
Georgetown University

Completed

V2 Receptor Effects on Fluid Regulation and Performance

Hyponatremia | Hypernatremia | Electrolyte Imbalance

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

Cirrhosis

Japan
Mayo Clinic

Completed

Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

Nephrolithiasis, Calcium Oxalate | Nephrolithiasis, Calcium Phosphate

United States
The Christ Hospital

Completed

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure (TUF)

Acute Decompensated Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Hyponatremia
Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Chronic Renal Failure

Japan
University of Michigan
Otsuka Pharmaceuticals

Withdrawn

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

Heart Failure

United States
Beijing Friendship Hospital
Chinese University of Hong Kong

Completed

Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia (OASIS)

Liver Cirrhosis | Hyponatremia

China
University of Florida
Otsuka America Pharmaceutical

Completed

Tolvaptan for Ascites in Cirrhotic Patients

Cirrhosis | Ascites

United States
Taiwan Otsuka Pharm. Co., Ltd

Completed

Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure

Cardiac-induced Edema

Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Regional Hospital Holstebro

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)

Cardiovascular Diseases | Nephropathy

Denmark
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Hunter Holmes Mcguire Veteran Affairs Medical Center
Otsuka America Pharmaceutical

Completed

Effect of Tolvaptan on Cognitive Function in Cirrhosis

Hepatic Encephalopathy | Cirrhosis | Hyponatremia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Edema, Cardiac

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan

Search clinical trials for: TOLVAPTAN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations